Quarter
Charts

IMMUNOVANT, INC.

IMVT

CIK 0001764013 · Quarterly mode · latest period FY2024 (Q1) (ending 2024-03-31) · sourced from SEC EDGAR

At a glance · FY2024 (Q1)

Revenue
$8M
↑+140.8% +$5Mvs FY2023 (Q1)
Gross Profit
$8M
↑+140.8% +$5Mvs FY2023 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0Insufficient data
  • Liquidity
    100Current Ratio 11.16 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.05x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +140.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$201K
investment in PP&E
Stock-based comp (TTM)
$56M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.05B
everything owned
Total liabilities
$66M
everything owed
Stockholders' equity
$986M
shareholder claim

Recent performance · 32 quarters

Revenue↑+140.8% +$5M
$8M
Net Income↑+0.4% +$487K
$-111M
Free Cash Flow↑+100.0% +$180K
$0

Drill down

IMVT Sankey

See IMMUNOVANT, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

IMVT Charts

32 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

IMVT Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics